Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes | Zendy

Osamu Saitô | Zendy; Takako Saitô | Zendy; Shinji Asakura | Zendy; Tetsu Akimoto | Zendy; Makoto Inoue | Zendy; Yukio Ando | Zendy; Shigeaki Muto | Zendy; Eiji Kusano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes

Author(s) -

Osamu Saitô,

Takako Saitô,

Shinji Asakura,

Tetsu Akimoto,

Makoto Inoue,

Yukio Ando,

Shigeaki Muto,

Eiji Kusano

Publication year - 2012

Publication title -

international journal of endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.652

H-Index - 23

eISSN - 1726-9148

pISSN - 1726-913X

DOI - 10.5812/ijem.3794

Subject(s) - medicine , raloxifene , bone remodeling , osteoporosis , endocrinology , hemodialysis , bone mineral , diabetes mellitus , renal osteodystrophy , kidney disease , cancer , estrogen receptor , breast cancer

Osteoporosis and chronic kidney disease are common conditions in older adults, and often occur concurrently. Bone disease is caused by increased bone turnover accompanying secondary hyperparathyroidism, and by factors such as bone metabolic disorder accompanying kidney disease and postmenopausal or age-related osteoporosis, even in hemodialysis patients. Raloxifene is commonly used for the treatment of postmenopausal osteoporosis in the general population, and may be a treatment option for osteoporosis in hemodialysis patients. However, the effects of raloxifene in hemodialysis patients with type 2 diabetes have not been examined in detail.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research